Faculty Bibliography

BACKGROUND CONTEXT: Frailty is an increasingly recognized characteristic that has been validated across many studies as influencing operative risk. Utilization of frailty indices can allow for its identification of which spine patients may be too high risk for surgical intervention. This may be especially useful when it comes to surgeries that are minimally invasive and are supposed to have decrease perioperative outcomes. PURPOSE: Identify MIS techniques effects in postoperative outcomes in TLIF patients. STUDY DESIGN/SETTING: Retrospective review of a prospective database. PATIENT SAMPLE: TLIF spine patients. OUTCOME MEASURES: Complications, length of stay (LOS), estimated blood loss (EBL).
METHOD(S): Pts that underwent a lumbar spine procedure in a single-center Comprehensive Spine Quality Database. Pts were stratified based on procedural approach (Open [OP] and Minimally invasive Surgery [MIS]). Frailty was then calculated for each resultant group by using 30 variables with a validated method. Based on these scores, pts were categorized no frailty [NF]: <0.09, frail [F]: 0.09-0.18, and severe frailty [SF] >0.18. Groups were then controlled for surgical invasiveness. Chi-squared tests identified the relationship between complications and length of stay among various frailty states given surgical approach (OP vs MIS). These patients were propensity score matched for levels fused. Hospital acquired complications (HACs) were identified based on frailty groups through the use of chi-squared and t-tests for other surgical factors. A logistic regression analysis identified the association between frailty status and surgical, regarding postoperative (postop) outcomes.
RESULT(S): A total of 1,300 TLIF spine patients were isolated (59yrs, 29.3kg/m2). After PSM for levels fused, there were 338 pts for both MIS and OP. MIS pts were older (56.1 vs 53.3; p<0.05) than Op pts and had similar BMI's (29.1 vs 29.7; respectively). However, OP received more posterior approaches and less anterior approaches than MIS pts (p<0.05). By surgical factors: MIS and OP patients had similar LOS (3 vs 2.9days) and EBL (282.8 vs 251.5cc) but differed by Op time (195.7 vs 247.1; p<0.05) respectively. Further breakdown by frailty displayed statistical significance between MIS and OP patients with MIS pts having more F (16% vs 12%) and SF pts (4.3% vs 1.9%) than OP (all p<0.05). FMIS patients had lower postop neurologic complications as compared to FOP pts (4.63% vs 14.8%). However, SFMIS patiens had more post-operative complications than SFOP pts (55.2% vs 23.1%) and increased a pt's likelihood of being SFMIS by 5.4x's (all p<0.05).
CONCLUSION(S): This study displays that when frailty status is taken into account, TLIF MIS patients benefit from this procedure type when analyzed against neurologic complications. However, these patients were seen to suffer more from postop complications but did not differ on any other specific complications or surgical variables. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright

BACKGROUND CONTEXT: Recombinant human bone morphogenetic protein 2 (rhBMP-2) is a popular biologic product used in transforaminal lumbar interbody fusion (TLIF) surgeries to promote fusion and avoid the morbidity associated with iliac crest autograft. However, use of rhBMP-2 and its effect on pseudarthrosis rates in TLIFs remains unknown. PURPOSE: To assess the rates of pseudarthrosis in open and MIS TLIF patients, with and without concurrent rhBMP-2 use. STUDY DESIGN/SETTING: Retrospective cohort study at a single academic institution. PATIENT SAMPLE: Included: 317 single level TLIF patients. Consisting of 157 open TLIF (OTLIF), 115 bilateral Wiltse MIS TLIF (WTLIF), and 45 hybrid midline MIS with percutaneous pedicle or cortical screws (MTLIF). OUTCOME MEASURES: Clinical characteristics, perioperative and postoperative outcomes, surgical procedure, rates of pseudarthrosis diagnosis, and revision for pseudarthrosis.
METHOD(S): Patients >=18 years old undergoing 1-level TLIF with minimum 1-year of clinical and radiographic follow up were included. Pseudarthrosis was determined using both radiographic and clinical evaluations. Differences between groups were assessed by ANOVA and chi squared analyses. Demographic and perioperative characteristics were analyzed by multivariate logistic regression.
RESULT(S): The cohort included 317 patients (mean age 59.68+/-13.29, F 52.7%). There was no significant difference in gender, BMI, or smoking status among groups (all p>.05). WTLIF had the lowest EBL (ml) (192.16+/-177.11mL vs 302.73+/-246.51 vs 363.85+/-370.49, respectively p=<0.001) and LOS (days) (2.88+/-1.76 vs 4.16+/-3.94 vs 4.03+/-1.97, respectively p=<0.001) compared to MTLIF and OTLIF. Further, MTLIF had the highest fluoroscopic dose (mGy) compared to WTLIF and OTLIF (52.85+/-40.49 vs 52.80+/-52.77 vs 15.21 +/- 24.53, respectively p=<0.001). MTLIF was also associated with the lowest BMP use compared to OTLIF and MTLIF (13.3% vs 23.6% vs 67.8%, respectively p=<.001). At minimum 1-year follow-up, there was no significant difference between the three different approaches with regards to pseudarthrosis rates (WTLIF 6.1%, MTLIF 8.9%, OTLIF 3.2%, p=0.249) or returns to the OR for pseudarthrosis (WTLIF 3.5%, MTLIF 6.7%, OTLIF 3.2%, p=0.546). Pseudarthrosis rates in patients treated with BMP was 5% (p = 0.881) for the cohort. There was no difference in reoperation for pseudarthrosis between patients who received BMP (2.5%) versus those who did not receive BMP (4.6%, P = 0.338). Multivariate Logistic regression analysis demonstrated no reduction in pseudarthosis related to BMP use (Odds Ratio 1.07 [CI 95% 0.228-5.04], p=0.929). Current or past smoking did not have an effect on use of BMP (p = 0.369) or significantly increase the rate of pseudarthrosis (p = 0.214), regardless of BMP use.
CONCLUSION(S): MP use did not reduce the rate of pseudarthrosis or the number of reoperations for pseudarthrosis in this cohort. No difference in pseudarthrosis rates between the three TLIF approaches was noted. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright

BACKGROUND CONTEXT: Screw placement in transforaminal interbody fusion (TLIF) and anterior lumbar interbody fusion (ALIF) can be done with open free hand (FH), fluoroscopy-guided (FG), spinal navigation (NAV), or robotic guided (RG) techniques. Varied techniques may affect perioperative (periop) outcomes. Few studies compare all four guidance techniques. PURPOSE: Compare the perioperative outcomes between FH, FG, NAV, and RG TLIF and ALIF. STUDY DESIGN/SETTING: Single center retrospective cohort study PATIENT SAMPLE: A total of 1,646 patients who underwent 1-2 level TLIF or 1-3 level ALIF from 2012-2019. OUTCOME MEASURES: Outcomes: registration failure, operative time (OT), radiation dosage (RD), estimated blood loss (EBL), length of stay (LOS), and periop complications, and retursn to OR up to 90 days.
METHOD(S): Patients undergoing 1-2 level TLIF or 1-3 level ALIF were included. Analysis of variance (ANOVA) and chi2test were used to analyze differences in outcomes with significance set at p<0.05. Post hoc Tukey (PHT) and Bonferroni (PHB) analysis were conducted when ANOVA or chi2 showed significance. RD was propensity matched for BMI. TLIFs underwent PSM for levels fused.
RESULT(S): A total of 1,202 1-2 level TLIFs were included (843 FH, 175 FG, 40 NAV, 144 RG) TLIFS. 444 1-3 level ALIFs were included: 337 FH, 25 FG, and 80 RG ALIFs. Demographics were similar amongst ALIF cohorts except significantly more FH-ALIF smokers and TLIF cohorts after propensity matching for levels fused. Amongst the TLIF Cohorts: OT and LOS longest in NAV (291.67+/-89.85 min; p <0.001 and 5.38+/-1.66 days p<0.001); EBL most in FG (482.43+/-530.79mL p=0.006). After PSM for BMI, there was no significant difference in RD. RG TLIF registration failed in 2.8% of cases. There were significantly more intraop (11.1%, p=0.008), and postop (45.8%; p<0.001) complications in the RG cohort, which showed high durotomy rates (6.9%; p=0.05) and instrumentation failure rates approaching significance (3.5%; p=0.058). The NAV group had the highest rate of SSI (2.5%; p = 0.045). Among the ALIF cohorts: RD, EBL, and LOS were similar; OT was longest in FG (395.7+/-113.7 p=0.001). There were significantly more intra- and postop complications in RG group (26.3%, p<0.001; 30%, p<0.001) and 13.8% of RG failed registration. Instrumentation failure was highest in FG (4.0% p=0.676), along with return to OR for instrumentation (8%, p = 0.183). Other periop complications and returns to OR were not significantly different.
CONCLUSION(S): NAV-TLIF had significantly differences in EBL, RD, periop complications, and return to OR 30 days. PSM for levels fused show postop complications rate remain significant with other factors and radiographic dosage remaining significant. RG TLIF and RG ALIF had the worst perioperative complications. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright

BACKGROUND CONTEXT: The thoracolumbar junction poses increased risk for high stress on upper lumbar discs when not adequately fused. However, controversy persists. This study evaluates outcomes of upper instrumented vertebrae (UIV) selection in the thoracic versus the upper lumbar spine when fusing to the sacrum. PURPOSE: To compare revision rates for thoracolumbar fusions to the sacrum and pelvis at 1- and 2-year follow-up, stratified by UIV selection. STUDY DESIGN/SETTING: Retrospective cohort study at a single institution. PATIENT SAMPLE: A total of 968 patients who had thoracolumbar fusion surgery between 2012-2018 with at least one year of postoperative follow-up. OUTCOME MEASURES: Reoperation rates from 1 and 2 years after revision surgery, reoperation diagnoses, body mass index (BMI), gender, Charleston Comorbidity Index (CCI), perioperative complications, ASA grade (ASA), operative time (OT), and blood loss (EBL).
METHOD(S): A retrospective review of patients undergoing revision spinal fusion with lower instrumented vertebra of S1 or pelvis between 2012-2018 at a single institution was performed. Patients with less than 1 year of follow-up after their index procedure were excluded from the analysis. Patients were categorized based on UIV into 6 groups: T9-T11, L1, L2, L3, L4, and L5. Demographic and operative data were collected and compared between the different UIV groups in each cohort using chi-squared and ANOVA tests. Revision rates at 1- and 2-year follow-up and the reasons for revision were compared between groups.
RESULT(S): There were 168 revision spinal fusions that reached 1-year follow-up, with 54 having UIV at T9-T11, 2 fusions L1 to sacrum, 26 fusions L2 to sacrum, 25 fusions L3 to sacrum, 36 fusions L4 to sacrum, 23 fusions L5 to sacrum. There was significant difference in patient age, with oldest in the L1 group (65.5+/-3.5) and youngest in the L5 group (51+/-15.4 p<0.001). There was significant difference in gender as both cases in L2 was female and L5 fusions only had 39.1% females (p = 0.006). There were no differences in BMI, CCI, and ASA. EBL (1891.6mL+/-1226.9mL p <0.001) and length of stay (7.7+/-3.0 p <0.001) was highest in the T9-11 UIV group. Operative time was highest in the L1 (464.5+/-174.7 p<0.001) UIV group. Levels added on top of prior fusion were calculated by subtracting UIV of index fusion to past UIV. Adding on 2 levels had a 1-year revision rate of 14.3% (p = 0.032), while adding on 1 level had a 0% 1-year revision rate. Adding on 4 levels had a revision rate of 12.5%, and adding on 7 levels had a 50% 1-year revision rate. At 2 years, adding on 1 level had revision rate of 25% and adding on 2 levels had a revision rate of 20% (p = 0.769). There is no statistically significant difference in perioperative complication rates between UIV groups (p = 0.114). The reoperation rate at 1 year for all levels was 9% and highest in UIV at L1 (50%, p=0.06). At 2-year follow-up, the reoperation rate for the total cohort was 32.34% with the highest revision rate for fusion from L2 to sacrum (53.85%) followed by (T9-T11 sacrum fusion 42.31%, L4 to sacrum31.71%, L3 to sacrum 30%, L5 to sacrum 25.04%, L1 to sacrum 25%, p=0.195). Grouping the UIV into lower thoracic (T9-T11), upper lumbar (L2-L3), and lower lumbar (L4-L5) showed similar revision rates at one year (p=0.697). At two years, lower thoracic group had a revision rate of 40% versus, 23.3% in the upper lumbar group (p =0.399).
CONCLUSION(S): There is no statistically significant difference in reoperation rates for revision thoracolumbar fusions to the sacrum/pelvis associated with different UIV selection. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright

OBJECTIVES/OBJECTIVE:The aim of this study was to determine the prevalence of myocarditis among patients presenting with myocardial infarction with nonobstructive coronary arteries (MINOCA) in relation to the angiographic severity of nonobstructive coronary artery disease (CAD). BACKGROUND:MINOCA represents about 6% of all cases of acute myocardial infarction. Myocarditis is a diagnosis that may be identified by cardiac magnetic resonance (CMR) imaging in patients with a provisional diagnosis of MINOCA. METHODS:A systematic review was performed to identify studies reporting the results of CMR findings in MINOCA patients with nonobstructive CAD or normal coronary arteries. Study-level and individual patient data meta-analyses were performed using fixed- and random-effects methods. RESULTS:Twenty-seven papers were included, with 2,921 patients with MINOCA; CMR findings were reported in 2,866 (98.1%). Myocarditis prevalence was 34.5% (95% confidence interval [CI]: 27.2% to 42.2%) overall and was numerically higher in studies that defined MINOCA as myocardial infarction with angiographically normal coronary arteries compared with a definition that permitted nonobstructive CAD (45.9% vs. 32.3%; p = 0.16). In a meta-analysis of individual patient data from 9 of the 27 studies, the pooled prevalence of CMR-confirmed myocarditis was greater in patients with angiographically normal coronary arteries than in those with nonobstructive CAD (51% [95% CI: 47% to 56%] vs. 23% [95% CI: 18% to 27%]; p < 0.001). Men and younger patients with MINOCA were more likely to have myocarditis. Angiographically normal coronary arteries were associated with increased odds of myocarditis after adjustment for age and sex (adjusted odds ratio: 2.30; 95% CI: 1.12 to 4.71; p = 0.023). CONCLUSIONS:Patients with a provisional diagnosis of MINOCA are more likely to have CMR findings consistent with myocarditis if they have angiographically normal coronary arteries.

PURPOSE/OBJECTIVE:For more than half of Crohn's disease patients, strictures will cause bowel obstructions that require surgery within 10 years of their initial diagnosis. This study utilizes computed tomography imaging and clinical data obtained at the initial emergency room visit to create a prediction model for progression to surgery in Crohn's disease patients with acute small bowel obstructions. METHODS:A retrospective chart review was performed for patients who presented to the emergency room with an ICD-10 diagnosis for Crohn's disease and visit diagnosis of small bowel obstruction. Two expert abdominal radiologists evaluated the CT scans for bowel wall thickness, maximal and minimal luminal diameters, length of diseased segment, passage of oral contrast, evidence of penetrating disease, bowel wall hyperenhancement or stratification, presence of a comb sign, fat hypertrophy, and small bowel feces sign. The primary outcome was progression to surgery within 6 months of presentation. The secondary outcome was time to readmission. RESULTS:Forty patients met the inclusion criteria, with 78% receiving medical treatment alone and 22% undergoing surgery within 6 months of presentation to the emergency room. Multivariable analysis produced a model with an AUC of 92% (95% CI 0.82-1.00), 78% sensitivity, and 97% specificity, using gender, body mass index, and the radiographic features of segment length, penetrating disease, and bowel wall hyperenhancement. CONCLUSIONS:The model demonstrates that routine clinical and radiographic data from an emergency room visit can predict progression to surgery, and has the potential to risk stratify patients, guide management in the acute setting, and predict readmission.

GOALS/OBJECTIVE:The goal of this study was to quantify the association between demographic factors and advanced colorectal cancer (CRC) in patients under age 50. BACKGROUND:CRC incidence in the United States has declined in older individuals but increased in those under age 50 (early-onset). More than 60% of early-onset CRC patients present with advanced disease (stage III/IV), but predictors of stage in this population are poorly defined. STUDY/METHODS:We analyzed CRC cases diagnosed between age 20 and 49 in the United States Surveillance, Epidemiology, and End Results (SEER) 18 database during 2004 to 2015. Logistic regression models were fit to assess the impact of age, sex, race, ethnicity, marital status, and cancer site on the probability of advanced disease. RESULTS:The analysis included 37,044 cases. On multivariable regression, age was inversely associated with advanced disease. Relative to 45 to 49-year-olds, 40 to 44-year-olds had 8% greater odds of having advanced CRC, and 20 to 24-year-olds had 53% greater odds. Asians, blacks, and Pacific Islanders had 10%, 12%, and 45% greater odds of advanced disease compared with whites. Compared with nonpartnered individuals, those with partners had 11% lower odds of advanced CRC. Both right-sided and left-sided colon cancer were more likely to be diagnosed at stage IV compared with rectal cancer. CONCLUSIONS:Among individuals with early-onset CRC, younger age, Asian, black, or Pacific Islander race, and being nonpartnered were predictors of advanced disease at presentation. Colon cancer was more likely to be diagnosed at stage IV than rectal cancer. Patient characteristics associated with advanced CRC may indicate both differences in tumor biology and disparities in health care access.

To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout.The New York Harbor VA computerized patient record system was searched to identify patients with an ICD-9 code for gout meeting at least 4 modified 1977 American Rheumatology Association gout diagnostic criteria. Patients were divided into subgroups based on >30 continuous days of allopurinol, versus no allopurinol. New diagnoses of diabetes, defined according to American Diabetes Association diagnostic criteria or clinical documentation explicitly stating a new diagnosis of diabetes, were identified during an observation period from January 1, 2000 through December 31, 2015.Six hundred six gout patients used allopurinol >30 continuous days, and 478 patients never used allopurinol. Over an average 7.9 ± 4.8 years of follow-up, there was no significant difference in diabetes incidence between the allopurinol and non-allopurinol groups (11.7/1000 person-years vs 10.0/1000 person-years, P = .27). A lower diabetes incidence in the longest versus shortest quartiles of allopurinol use (6.3 per 1000 person-years vs 19.4 per 1000 person-years, P<.0001) was attributable to longer duration of medical follow-up.In this study, allopurinol use was not associated with decreased diabetes incidence. Prospective studies may further elucidate the relationship between hyperuricemia, gout, xanthine oxidase activity, and diabetes, and the potential impact of gout treatments on diabetes incidence.

PURPOSE/OBJECTIVE:The right ventricular outflow tract (RVOT) velocity time integral (VTI), an echocardiographic measure of stroke distance, correlates with cardiac index. We sought to determine the prognostic significance of low RVOT VTI on clinical outcomes among patients with acute pulmonary embolism (PE). MATERIALS AND METHODS/METHODS:We conducted a retrospective review of echocardiograms on Pulmonary Embolism Response Team (PERT) activations at our institution. The main outcome was a composite of death, cardiac arrest, or hemodynamic deterioration. RESULTS:Of 188 patients, 30 met the combined outcome (16%) and had significantly lower RVOT VTI measurements (9.0 cm v 13.4 cm, p < 0.0001). The AUC for RVOT VTI at a cutoff of 10 cm was 0.78 (95% CI 0.67-0.90) with a sensitivity, specificity, negative predictive value, and positive predictive value of 0.72, 0.81, 0.94, and 0.42, respectively. Fifty-two patients of the cohort were classified as intermediate-high-risk PE and 21% of those met the combined outcome. RVOT VTI was lower among outcome positive patients (7.3 cm v 10.7 cm, p = 0.02). CONCLUSIONS:Low RVOT VTI is associated with poor clinical outcomes among patients with acute PE.

Air pollution is a major contributor to cardiovascular morbidity and mortality. Fine particulate matter <2.5 µm in diameter may be a modifiable risk factor for hypertension. The benefits of in-home air filtration on systolic blood pressure (BP) and diastolic BP are unclear. To examine the effects of in-home personal air cleaner use on fine particulate exposure and BP, we queried PubMed, Web of Science, Cochrane Central Register, Inspec, and EBSCO GreenFILE databases for relevant clinical trials. Included studies were limited to nonsmoking participants in smoke-free homes with active or sham filtration on indoor fine particulate concentrations and changes in systolic and diastolic BP. Of 330 articles identified, 10 trials enrolling 604 participants who met inclusion criteria were considered. Over a median 13.5 days, there was a significant reduction of mean systolic BP by ≈4 mm Hg (-3.94 mm Hg [95% CI, -7.00 to -0.89]; P=0.01) but a nonsignificant difference in mean diastolic BP (-0.95 mm Hg [95% CI, -2.81 to 0.91]; P=0.32). Subgroup analyses indicated no heterogeneity of effect by age, level of particulate exposure, or study duration. Given the variation in study design, additional study is warranted to confirm and better quantify the observed benefits in systolic BP found with personal air cleaner use.